API
< Back to all clusters
[HEALTH] · Germany, Austria, Italy, Netherlands, United States · 2 sources

started · updated

Medical research advances in heart valve studies and risk assessment

An international clinical study, the Paradigm trial, has received regulatory approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM) to test the DurAVR heart valve. Developed by Anteris Technologies, this balloon-expandable valve uses a biomimetic design intended to replicate the natural shape of an aortic valve to achieve more physiological blood flow patterns.

The randomized controlled trial aims to enroll approximately 1,000 patients with severe aortic stenosis. Participants will be assigned to receive either the DurAVR valve or a commercially available TAVR valve, such as those from Edwards Lifesciences or Medtronic. The study's primary endpoint is to demonstrate non-inferiority regarding mortality, stroke, and cardiovascular hospitalizations after one year.

In a separate cardiology development, a study led by MedUni Wien suggests that current clinical guidelines may underestimate risks for patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Research involving 1,101 patients across Austria, Italy, Germany, and the Netherlands indicates that the threshold for high-risk mitral valve insufficiency in ATTR-CM patients is a regurgitant volume of 38 ml per beat, rather than the standard 45 ml. Applying this disease-specific threshold identifies 21 percent of the studied patients as high-risk.

Entities

Anteris Technologies · BfArM · Edwards Lifesciences · MedUni Wien · Medtronic